Last reviewed · How we verify
Maseptol (methylparaben)
Maseptol (generic name: methylparaben) is a Standardized Chemical Allergen drug. It is currently in unknown development.
Maseptol works by binding to carbonic anhydrase 7, a protein involved in various cellular processes.
Maseptol, also known as methylparaben, is a small molecule standardized chemical allergen. It targets carbonic anhydrase 7, but its exact mechanism of action is unclear. Maseptol's commercial status and approved indications are unknown. As a standardized chemical allergen, it may be used to diagnose or treat allergic reactions. However, its safety profile and pharmacokinetic properties are not well established.
At a glance
| Generic name | methylparaben |
|---|---|
| Drug class | Standardized Chemical Allergen |
| Target | Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 14 |
| Therapeutic area | Metabolic |
| Phase | unknown |
Mechanism of action
Think of it like a key fitting into a lock. Maseptol is the key, and carbonic anhydrase 7 is the lock. When they bind together, it can affect how the protein works, which may help diagnose or treat allergic reactions.
Approved indications
Common side effects
Key clinical trials
- Skin Barrier Function and Inflammation in Aging: The BIA Study (PHASE4)
- Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain (PHASE2)
- Bacterial Cellulose-monolaurin Hydrogel for Acute Radiation Dermatitis (NA)
- Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy (PHASE1)
- Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus (PHASE2)
- Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old (PHASE3)
- Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease (NA)
- Copaíba-based Mouthwash in Oral Mucotitis Prevention and Treatment in Oral Cancer Patients During Radioteraphy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maseptol CI brief — competitive landscape report
- Maseptol updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Maseptol
What is Maseptol?
How does Maseptol work?
What is the generic name of Maseptol?
What drug class is Maseptol in?
What development phase is Maseptol in?
What does Maseptol target?
Related
- Drug class: All Standardized Chemical Allergen drugs
- Target: All drugs targeting Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 14
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing